Latest news with #IndianPharmaceuticalMarket
Mint
5 days ago
- Business
- Mint
Stocks to buy: Lupin, Aurobindo, Max Healthcare among Axis Sec's top pharma & hospital picks post strong Q4
Stocks to buy: Axis Securities has reaffirmed its bullish view on the pharmaceuticals and hospital sectors in its latest report following the March quarter results, reiterating confidence in select stocks such as Lupin, Aurobindo Pharma, Max Healthcare, and Fortis Healthcare, citing emerging opportunities supported by strong fundamentals and favorable industry dynamics. The brokerage noted that the pharmaceuticals industry appears well-positioned for FY26 and beyond, supported by a strong product pipeline in biosimilars, GLP-1, and peptides. It highlighted that chronic therapies continue to outperform the overall Indian Pharmaceutical Market (IPM), contributing to sustained growth. Additionally, margins are expected to remain stable to improving, aided by a favorable product mix and easing input costs. The US generics business also shows continued strength, with leading players like Lupin and Aurobindo Pharma maintaining meaningful market shares despite ongoing competitive pressures and anticipated low single-digit price erosion. Stock Name Rating Latest closing price Target price Upside Potential Aurobindo Pharma Buy ₹ 1,138 ₹ 1,500 31.2% Lupin Buy ₹ 1,944 ₹ 2,500 28.6% Max Healthcare Institute Buy ₹ 1,147 ₹ 1315 15% Fortis Healthcare Buy ₹ 729 ₹ 775 6.3% Axis believes that companies with a differentiated portfolio and greater exposure to complex generics are likely to outperform in this environment. Consequently, it maintained 'buy' on Aurobindo Pharma and Lupin with a 'buy' rating and has a target price of ₹ 1,500 and ₹ 2500, respectively. In the hospital space, Axis Securities observed that the growth trajectory remains strong, backed by structural tailwinds. These include increased surgical volumes, an improved payer mix, and rising demand for high-growth therapies such as cancer and cardiac care—all of which are contributing to higher ARPOB (average revenue per occupied bed) and occupancy rates. The brokerage expects industry ARPOB to grow at 6–7% annually, with a 100-basis-point improvement in occupancy rates, supporting further margin expansion. Max Healthcare and Fortis Healthcare are viewed as well-positioned to benefit from these secular growth trends, given their scalable operations and strong execution across key metrics. Therefore, it retained a 'buy' recommendation on both the stocks, with a price target of ₹ 1,315 on Max Healthcare shares and ₹ 775 apiece on Fortis Healthcare shares. The pharmaceutical sector delivered a healthy performance in Q4FY25, with revenue growth of 12.3% YoY and 2.3% QoQ, driven primarily by the India business (11.2% YoY). The US generics business recorded 7.7% YoY growth in CC terms, aided by the launch of niche products and price stability. Improvement in gross margins to 66.1% (up 95 bps YoY) was underpinned by a favourable mix shift, muted price erosion, and stable input costs, said Axis Securities. In the hospital sector, revenue grew by 20% YoY and 2% QoQ, supported by higher occupancy rates (+60 bps YoY), an ARPOB increase of 6% YoY, and an 18% rise in operational bed days. Notably, the brokerage stated that the contribution of insurance payers rose to 33%, indicating deeper penetration and improved affordability. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%
JB Chemicals and Pharmaceuticals reported a 15 per cent year-on-year (Y-o-Y) increase in net profit for Q4 FY25, reaching ₹145.6 crore, while revenue from operations rose 10 per cent Y-o-Y to ₹949.4 crore. Sequentially, net profit declined 10.3 per cent, while revenue fell 1.4 per cent. For the full financial year (FY25), consolidated net profit rose 19.3 per cent to ₹659.5 crore, and revenue from operations increased 12.4 per cent to ₹3,918 crore. Nikhil Chopra, CEO and wholetime director of JB Pharma, said: 'We have closed the financial year FY25 on a strong note, in line with our strategic intent. Our domestic business continues to be one of the fastest growing in the Indian Pharmaceutical Market (IPM). With 75 per cent of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.' The stock rose 1.94 per cent to ₹1,610.50 apiece on the BSE. The results were announced after market hours on Wednesday. In Q4, the company's domestic business registered 11 per cent Y-o-Y growth to ₹519 crore. According to IQVIA data, JB Pharma grew 13 per cent Y-o-Y in the quarter, nearly double the Indian Pharmaceutical Market (IPM) growth of 7 per cent. Excluding its ophthalmology portfolio, JB Pharma's growth stood at 12 per cent. Prescription volumes rose 7 per cent Y-o-Y during the quarter. The chronic portfolio recorded strong growth of 16 per cent, while the acute segment grew 10 per cent, as per IQVIA. The ophthalmology segment was a standout performer, growing 22 per cent Y-o-Y to ₹56 crore, compared to ₹46 crore a year earlier. The international business delivered revenue of ₹430 crore in Q4 FY25, up 9 per cent Y-o-Y. Within this, the international formulations business rose 6 per cent to ₹282 crore, driven by double-digit growth in markets like Russia and in the branded generics export segment. JB Pharma's contract development and manufacturing (CDMO) business posted 18 per cent growth during the quarter, with revenue of ₹129 crore and a robust order book for the coming quarters. However, the active pharmaceutical ingredient (API) business remained muted, contributing ₹19 crore in sales. The combined share of the domestic and CDMO businesses increased to 69 per cent of overall revenue, up from 55 per cent in FY21. The domestic business grew 20 per cent annually to ₹2,269 crore, led by sustained demand across therapeutic areas. Excluding ophthalmology, the domestic portfolio registered 13 per cent growth. JB Pharma's international business rose 4 per cent to ₹1,649 crore in FY25, with Russia and branded generics exports recording healthy double-digit growth. The CDMO segment also delivered strong performance in the second half of the fiscal.
India Gazette
10-05-2025
- Business
- India Gazette
Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report
New Delhi [India], May 10 (ANI): The Indian Pharmaceutical Market continued its upward momentum in April 2025, registering a strong 7.8 per cent year-on-year growth with total sales reaching Rs 19,711 crore, according to a report by Pharmatrack. The monthly performance added an impressive Rs 1,424 crore in incremental sales, underscoring the sector's sustained resilience and demand, the report added. According to the report, the sales growth was primarily driven by price-led expansion, followed by the impact of new product introductions (NIS). On a Moving Annual Total (MAT) basis, the report added that the industry surged to Rs 2,27,361 Crore, reflecting a year-over-year growth of 8.3 per cent and a healthy 10.3 per cent Compound annual growth rate (CAGR), highlighting the sector's resilience and long-term growth potential. Therapeutic segments powering this momentum on April 25 include Cardiac, Neuro/CNS, Blood-Related, Anti-Neoplastics, Ophthalmology/Otology, and Urology, reinforcing the strategic importance of speciality and chronic therapies in driving market expansion. This performance highlights the industry's effective pricing strategies to manage cost pressures and sustain topline growth, even as overall volume growth remained modest at 0.4 per cent, added the report. As per the finding of the report, among therapy areas, Cardiac and Anti-Infectives posted notable volume gains in April. The report highlights that the cardiac therapy segment shows a strong trend, propelled by sustained demand in chronic disease management, particularly for Anti-Hypertensives, Lipid Lowering agents and Heart Failure therapies. Meanwhile, Anti-Infectives experienced volume uplift tied to acute care needs, likely influenced by seasonal infections and localised outbreaks. Going further, the report adds that from a pricing standpoint, Respiratory therapy led with a 6.6 per cent price increase, followed closely by Cardiac and Gastrointestinal therapies, reflecting pricing dynamics in high-demand categories. Stomatologicals emerged as a standout in new product performance, registering a 7.7 per cent growth, focusing on launches in specialised care areas where competition is relatively low and demand is evolving, the report added.(ANI)
Mint
01-05-2025
- Business
- Mint
Corona Remedies files draft papers with Sebi for ₹800 crore IPO; Details here
Pharmaceutical company Corona Remedies has submitted preliminary documents to the Securities and Exchange Board of India (Sebi) to seek approval for launching an initial public offering (IPO) worth ₹ 800 crore. The IPO will be entirely an offer for sale (OFS), meaning that no new shares will be issued. Instead, promoters and existing investors will sell their stakes, as detailed in the draft red herring prospectus (DRHP). As per the DRHP, the promoter group headed by Dr. Kirtikumar Laxmidas Mehta, along with current investor ChrysCapital's affiliates—Sepia Investments, Anchor Partners, and Sage Investment Trust—will offload shares in the proposed offering. ChrysCapital currently owns a 27.5% stake in Corona. The IPO is being managed by JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company as the lead book-running managers. Ahmedabad-headquartered Corona Remedies engages in the development, manufacturing, and marketing of pharmaceutical products across various therapeutic segments, including women's health, cardiovascular and diabetes care, pain management, and urology. A CRISIL report ranked the company as the second fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) based on domestic sales from MAT December 2021 to MAT December 2024. As of December 31, 2024, the company's portfolio comprised 67 brands, and it reported revenues of ₹ 1,014.5 crore for FY24. As of December 31, 2024, its broad product portfolio includes 67 brands that serve various therapeutic fields, including women's healthcare, cardio-diabetes, pain management, urology, and more. The company's promoters are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta.
Mint
01-05-2025
- Business
- Mint
Corona Remedies files draft papers with Sebi for ₹800 crore IPO; Details here
Pharmaceutical company Corona Remedies has submitted preliminary documents to the Securities and Exchange Board of India (Sebi) to seek approval for launching an initial public offering (IPO) worth ₹ 800 crore. The IPO will be entirely an offer for sale (OFS), meaning that no new shares will be issued. Instead, promoters and existing investors will sell their stakes, as detailed in the draft red herring prospectus (DRHP). As per the DRHP, the promoter group headed by Dr. Kirtikumar Laxmidas Mehta, along with current investor ChrysCapital's affiliates—Sepia Investments, Anchor Partners, and Sage Investment Trust—will offload shares in the proposed offering. ChrysCapital currently owns a 27.5% stake in Corona. The IPO is being managed by JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company as the lead book-running managers. Ahmedabad-headquartered Corona Remedies engages in the development, manufacturing, and marketing of pharmaceutical products across various therapeutic segments, including women's health, cardiovascular and diabetes care, pain management, and urology. A CRISIL report ranked the company as the second fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) based on domestic sales from MAT December 2021 to MAT December 2024. As of December 31, 2024, the company's portfolio comprised 67 brands, and it reported revenues of ₹ 1,014.5 crore for FY24. As of December 31, 2024, its broad product portfolio includes 67 brands that serve various therapeutic fields, including women's healthcare, cardio-diabetes, pain management, urology, and more. The company's promoters are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 1 May 2025, 09:42 AM IST
